Cargando…

Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer

BACKGROUND: The iMATRIX-atezolizumab study was a phase I/II, multicenter, open-label study designed to assess the safety and pharmacokinetics of atezolizumab in pediatric and young adult patients. We describe the pharmacokinetics (PK), exposure-safety, and immunogenicity of atezolizumab in pediatric...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shemesh, Colby S., Chanu, Pascal, Jamsen, Kris, Wada, Russ, Rossato, Gianluca, Donaldson, Francis, Garg, Amit, Winter, Helen, Ruppel, Jane, Wang, Xin, Bruno, Rene, Jin, Jin, Girish, Sandhya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6868826/ https://www.ncbi.nlm.nih.gov/pubmed/31753029 http://dx.doi.org/10.1186/s40425-019-0791-x

Ejemplares similares

Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors
por: Huang, Weize, et al.
Publicado: (2022)

Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1)
por: Wu, Benjamin, et al.
Publicado: (2021)

Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2)
por: Peters, Solange, et al.
Publicado: (2021)

Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma
por: Lu, Dan, et al.
Publicado: (2020)

Integrated Two‐Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non‐Hodgkin Lymphoma
por: Lu, Dan, et al.
Publicado: (2019)

Pan‐cancer population pharmacokinetics and exposure‐safety and ‐efficacy analyses of atezolizumab in patients with high tumor mutational burden
por: Shemesh, Colby S., et al.
Publicado: (2020)

Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting
por: Morrissey, Kari M., et al.
Publicado: (2019)

Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma
por: Shemesh, Colby S., et al.
Publicado: (2020)

Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody‐Drug Conjugates
por: Li, Chunze, et al.
Publicado: (2020)

First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination
por: Tella, Sri Harsha, et al.
Publicado: (2022)

Towards optimal design of anti-malarial pharmacokinetic studies
por: Simpson, Julie A, et al.
Publicado: (2009)

Atezolizumab-associated Dermatomyositis in Advanced Small-cell Lung Carcinoma
por: Yamaguchi, Yoshitaka, et al.
Publicado: (2021)

Optimal designs for population pharmacokinetic studies of oral artesunate in patients with uncomplicated falciparum malaria
por: Jamsen, Kris M, et al.
Publicado: (2011)

Tumor Time‐Course Predicts Overall Survival in Non‐Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Follow‐Up Time
por: Netterberg, Ida, et al.
Publicado: (2020)

Allelic variation in HLA‐DRB1 is associated with development of antidrug antibodies in cancer patients treated with atezolizumab that are neutralizing in vitro
por: Hammer, Christian, et al.
Publicado: (2022)

Atezolizumab-associated encephalitis in metastatic lung adenocarcinoma: a case report
por: Yamaguchi, Yoshitaka, et al.
Publicado: (2020)

Optimal designs for population pharmacokinetic studies of the partner drugs co-administered with artemisinin derivatives in patients with uncomplicated falciparum malaria
por: Jamsen, Kris M, et al.
Publicado: (2012)

Population pharmacokinetics of bevacizumab in cancer patients with external validation
por: Han, Kelong, et al.
Publicado: (2016)

Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab
por: Tang, Weifeng, et al.
Publicado: (2023)

Atezolizumab Induces Necroptosis and Contributes to Hepatotoxicity of Human Hepatocytes
por: Endo, Yukinori, et al.
Publicado: (2023)

Results of a Dose‐Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non–Small Cell Lung Cancer
por: Felip, Enriqueta, et al.
Publicado: (2021)

Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review
por: Ahmed, Faiza, et al.
Publicado: (2021)

Atezolizumab-Induced Autoimmune Diabetes in a Patient With Metastatic Lung Cancer
por: Sothornwit, Jin, et al.
Publicado: (2019)

Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumab
por: Nabbi, Arash, et al.
Publicado: (2023)

Two Cases of Atezolizumab-Induced Hypophysitis
por: Kanie, Keitaro, et al.
Publicado: (2017)

Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy
por: Lambert, Nicolas, et al.
Publicado: (2022)

Pharmacokinetic and exposure–response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer
por: Kirschbrown, Whitney P., et al.
Publicado: (2019)

Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics
por: Liu, Stephanie N., et al.
Publicado: (2021)

Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development
por: Zaloumis, Sophie, et al.
Publicado: (2012)

A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab
por: Rosario, Maria, et al.
Publicado: (2017)

Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab
por: Kimball, A.B., et al.
Publicado: (2019)

Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform
por: Ko, Andrew H, et al.
Publicado: (2023)

Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin(®)), a HER2-targeted monoclonal antibody, in patients with a variety of solid tumors
por: Quartino, Angelica L., et al.
Publicado: (2018)

Collagenous colitis and atezolizumab therapy: an atypical case
por: Gallo, Antonella, et al.
Publicado: (2020)

Atezolizumab-Induced Aseptic Meningitis in Patients with NSCLC
por: Toyozawa, Ryo, et al.
Publicado: (2020)

ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer
por: Kyte, J. A., et al.
Publicado: (2020)

Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects
por: Gardin, Anne, et al.
Publicado: (2018)

Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity.
por: Chinol, M., et al.
Publicado: (1998)

Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Belatacept in Adult Kidney Transplant Recipients
por: Shen, Jinshan, et al.
Publicado: (2013)

Pharmacokinetics and Immunogenicity of Broadly Neutralizing HIV Monoclonal Antibodies in Macaques
por: Rosenberg, Yvonne, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_bg7k9sjlki1413bc7jjcpl2gug